THE US Food and Drug
Administration has approved
Bayer’s Xarelto (rivaroxaban
tablets) for the prophylaxis of deep
vein thrombosis which may lead to
a pulmonary embolism in patients
undergoing knee or hip
replacement surgery.
Xarelto is the only new oral
anticoagulant with US approval in
this indication.
It’s approved for use at a 10mg
dose with one tablet per day for 35
days following hip replacement, or
12 days following knee
replacement surgery.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jul 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jul 11
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.